2 not yet recruiting, 1 active not recruiting, 1 recruiting, 1 suspended. 3 Phase 2, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Not applicable | 2 | Not yet recruiting 1, Suspended 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Neurofibromatosis 1 (NF1): new trials by email Literature Review of Neurofibromatosis 1 (NF1) trials Research Report on Neurofibromatosis 1 (NF1)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs) GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling) - Neurofibromatosis 1 (NF1), Neurofibromatosis Type I | Not applicable | Suspended | Massachusetts General Hospital | 10 | 2027-01-01 | 2026-06-04 |
| Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1) | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 55 | 2027-01-01 | 2026-10-05 |
| Cognitive Intervention for Children and Adolescents With NF1 Unstuck and On Target! - Neurofibromatosis 1 (NF1), Executive Function (Cognition) | Not applicable | Not yet recruiting | The Hospital for Sick Children | 60 | 2026-09-28 | 2026-10-13 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Selumetinib - Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 36 | 2016-01-07 | 2026-09-15 |
Neurofibromatosis 1 (5) · Glioblastoma (1) · Glioma (1) · Neurofibroma, Plexiform (1) · Neurofibromatoses (1) · Neurofibrosarcoma (1) · Psychological Well-Being (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Heredodegenerative Disorders, Nervous System (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Nerve Tissue (5) · Neoplastic Syndromes, Hereditary (5) · Nerve Sheath Neoplasms (5) · Nervous System Diseases (5) · Neurocutaneous Syndromes (5) · Neurodegenerative Diseases (5) · Neurofibroma (5) · Neuromuscular Diseases (5) · Peripheral Nervous System Diseases (5) · Neurofibromatoses (4)
AZD 6244 (2) · Lasers (1) · Lasers, Solid-State (1) · Radiation (1) · mirdametinib (1)
AeRang Kim (1) · Massachusetts General Hospital (1) · National Cancer Institute (NCI) (1) · The Hospital for Sick Children (1) · University of Alabama at Birmingham (1)
United States (4)
AeRang Kim, MD, PhD (1) · Brigitte C Widemann, M.D. (1) · Busi Zapparoli, Ph.D., C.Psych. (1) · Girish Dhall, MD (1) · Richard R. Anderson, MD (1)